Myriad myPath™ Melanoma improves diagnosis and treatment plans

Results from a prospective clinical utility study of the Myriad myPath Melanoma test presented at the 2014 American Society of Dermatopathology annual meeting found a 43 percent reduction in indeterminate diagnoses and a 49 percent change in physicians’ treatment recommendations for patients. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *